Skip to main content
EnglishEN
European Commission logo print header

Host directed medicine in invasive fungal infection

Project description

DEENESFRITPL

Host-directed approach to cure invasive fungal infections

Invasive fungal infections (IFIs) represent a major threat in immunocompromised and critically ill adult and paediatric patients. Experts believe that a host-directed approach could help to improve the current situation. The EU-funded HDM-FUN project proposes a transdisciplinary approach to identify critical factors for host-directed medical interventions in IFIs. The overall objective is to identify host-pathogen factors essential for immunotherapy and prophylaxis, so as to enable the design of novel therapeutic and preventive host-directed medicine approaches for patients with lethal invasive fungal infection in intensive care. HDM-FUN brings together leading scientists and clinical researchers to study genetics and transcription host factors, metabolome and microbiome immune modulators and host pathogen interactions at molecular and cellular level that determine the susceptibility and treatment outcome of patients with fungal infection.

Objective

Despite novel treatment options and development of diagnostic tools invasive fungal infections (IFI) are still associated with an unacceptably high mortality and morbidity. Experts believe that a host directed approach is needed to overcome this problem. HDM-FUN proposes a transdisciplinary approach to identify host-pathogen factors (HPFs) needed for host directed medical interventions in IFI and will be the first of its kind.
The overall concept is to identify host-pathogen factors in the setting of immunotherapy and prophylaxis that will allow the design for tailored novel therapeutic and preventive host-directed medicine approaches for patients with lethal invasive fungal infection in the intensive care.
Specific objectives:
1. To identify host-pathogen factors that correlate with disease, and correlate them with preventive or immunotherapy- based strategies to stratify patients for personalized host-directed treatment options.
2. Two clinical trials of host-directed medicine approaches; an immunotherapy trial in patients with candidemia and a prospective observational trial for prophylaxis in patients with influenza at risk for aspergillosis.
3. To set-up a centrally managed biobank with samples of the patients enrolled in both clinical trials, and to standardize experimental procedures, protocols and centralize analysis.
4. To establish a unique infrastructure aimed to: explore host-directed medicine approaches in IFI, evaluate their impact on patients and health care, translate research efforts to clinical practice by designing point of care tests and teaching medical professionals.
HDM-FUN brings together top scientists and clinical researchers to unravel host factors (genetics and transcription), immune modulators (metabolome, microbiome), and host pathogen interactions (genetics, metabolomics, immunology, signalling pathways, phagosome biogenesis, and inflammasome regulation) that determine the susceptibility and outcome of patients with fungal infection.

Fields of science

Keywords

Programme(s)

Topic(s)

Call for proposal

H2020-SC1-BHC-2018-2020

See other projects for this call

Sub call

H2020-SC1-2019-Two-Stage-RTD

Funding Scheme

RIA - Research and Innovation action

Coordinator

STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM
Net EU contribution
€ 3 288 700,00
Address
GEERT GROOTEPLEIN 10 ZUID
6525 GA Nijmegen
Netherlands

See on map
Region
Oost-Nederland Gelderland Arnhem/Nijmegen
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 3 288 700,00

Participants (17)

Share this page

Download

Last update: 15 January 2024

My Booklet

Permalink: https://cordis.europa.eu/project/id/847507

European Union, 2024